Newlink Genetics Corporation (NASDAQ:NLNK) Reports Decline in Sellers; Strong Momentum for Longs

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Investors sentiment decreased to 0.82 in Q1 2019. Its down 0.15, from 0.97 in 2018Q4. It dropped, as 14 investors sold NewLink Genetics Corporation shares while 20 reduced holdings. 11 funds opened positions while 17 raised stakes. 12.32 million shares or 2.55% less from 12.64 million shares in 2018Q4 were reported.
671,075 were reported by Panagora Asset. State Of Wisconsin Board stated it has 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Deutsche State Bank Ag accumulated 35,576 shares. Bogle Inv Management Ltd Partnership De holds 0% or 23,047 shares. Pennsylvania Tru holds 0.01% or 2,489 shares. Acadian Asset Management Ltd Liability owns 404,083 shares for 0% of their portfolio. 31,269 are held by Virtu Limited Liability Company. New York State Common Retirement Fund reported 21,800 shares. Morgan Stanley accumulated 0% or 71,270 shares. Dimensional Fund Advsrs Ltd Partnership owns 316,045 shares. Voya Invest Mngmt Llc has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK). Fenimore Asset Mngmt holds 0% or 12,321 shares. Alliancebernstein L P holds 0% or 42,600 shares in its portfolio. Canada Pension Plan Invest Board invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). State Street Corp owns 526,561 shares for 0% of their portfolio.

The stock of Newlink Genetics Corporation (NASDAQ:NLNK) registered a decrease of 4.22% in short interest. NLNK’s total short interest was 1.51 million shares in July as published by FINRA. Its down 4.22% from 1.57M shares, reported previously. With 278,600 shares average volume, it will take short sellers 5 days to cover their NLNK’s short positions. The short interest to Newlink Genetics Corporation’s float is 5.76%.

It closed at $1.47 lastly. It is down 69.83% since July 12, 2018 and is downtrending. It has underperformed by 74.26% the S&P500.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $54.80 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: which released: “NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued – Yahoo Finance” on April 26, 2019, also with their article: “Celgene (CELG) Hits 52-Week High, Can the Run Continue? – Nasdaq” published on June 18, 2019, published: “NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019 – GlobeNewswire” on April 24, 2019. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: and their article: “Key events next week – healthcare – Seeking Alpha” published on March 22, 2019 as well as‘s news article titled: “NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback – Seeking Alpha” with publication date: May 17, 2018.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.